Compile Data Set for Download or QSAR
maximum 50k data
Found 585 of affinity data for UniProtKB/TrEMBL: P54840
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM635210(US11814367, Compound 659)
Affinity DataIC50:  1.75E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634938(US11814367, Compound 387)
Affinity DataIC50:  3.62E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM635119(US11814367, Compound 568 | US11814367, Compound 57...)
Affinity DataIC50:  4.12E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM635029(US11814367, Compound 478)
Affinity DataIC50:  6.82E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634926(US11814367, Compound 375)
Affinity DataIC50: >7.74E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634965(US11814367, Compound 414)
Affinity DataIC50:  7.87E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM635129(US11814367, Compound 578)
Affinity DataIC50:  7.93E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634919(US11814367, Compound 368)
Affinity DataIC50: >8.23E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634942(US11814367, Compound 391)
Affinity DataIC50:  8.93E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634940(US11814367, Compound 389)
Affinity DataIC50: >9.03E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM635135(US11814367, Compound 584)
Affinity DataIC50: >9.18E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM635229(US11814367, Compound 678 | US11814367, Compound 68...)
Affinity DataIC50:  9.30E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM635119(US11814367, Compound 568 | US11814367, Compound 57...)
Affinity DataIC50:  9.42E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM635147(US11814367, Compound 596)
Affinity DataIC50: >9.67E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634552(US11814367, Compound 1)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634553(US11814367, Compound 2)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634554(US11814367, Compound 3)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634557(US11814367, Compound 6)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634558(US11814367, Compound 7)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634559(US11814367, Compound 8)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634560(US11814367, Compound 9)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634561(US11814367, Compound 10)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634562(US11814367, Compound 11)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634564(US11814367, Compound 13)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634565(US11814367, Compound 14)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634566(US11814367, Compound 15)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634567(US11814367, Compound 16)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634568(US11814367, Compound 17)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634569(US11814367, Compound 18)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634572(US11814367, Compound 21)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634573(US11814367, Compound 22 | US11814367, Compound 221)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634574(US11814367, Compound 23)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634575(US11814367, Compound 24)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634576(US11814367, Compound 25)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634577(US11814367, Compound 26 | US11814367, Compound 28)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634578(US11814367, Compound 27)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634577(US11814367, Compound 26 | US11814367, Compound 28)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634580(US11814367, Compound 29)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634582(US11814367, Compound 31)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634583(US11814367, Compound 32)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634584(US11814367, Compound 33)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634585(US11814367, Compound 34)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634586(US11814367, Compound 35)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634587(US11814367, Compound 36)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634588(US11814367, Compound 37 | US11814367, Compound 38)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634588(US11814367, Compound 37 | US11814367, Compound 38)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634591(US11814367, Compound 40)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634592(US11814367, Compound 41)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634595(US11814367, Compound 44)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetGlycogen [starch] synthase, liver(Homo sapiens)
Maze Therapeutics

US Patent
LigandPNGBDBM634597(US11814367, Compound 46)
Affinity DataIC50: >1.00E+5nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 585 total ) | Next | Last >>
Jump to: